Drug Type Small molecule drug |
Synonyms + [1] |
Target |
Action inhibitors |
Mechanism Cardiac myosin inhibitors |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
RegulationBreakthrough Therapy (United States), Orphan Drug (United States), Priority Review (China) |
Molecular FormulaC18H19N5O2 |
InChIKeyIOVAZWDIRCRMTM-OAHLLOKOSA-N |
CAS Registry2364554-48-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hypertrophic obstructive cardiomyopathy | NDA/BLA | China | 15 Oct 2024 | |
Hypertrophic Cardiomyopathy without Obstruction | Phase 3 | Israel | 30 Aug 2023 | |
Hypertrophic Cardiomyopathy without Obstruction | Phase 3 | Germany | 30 Aug 2023 | |
Hypertrophic Cardiomyopathy without Obstruction | Phase 3 | China | 30 Aug 2023 | |
Hypertrophic Cardiomyopathy without Obstruction | Phase 3 | Poland | 30 Aug 2023 | |
Hypertrophic Cardiomyopathy without Obstruction | Phase 3 | Portugal | 30 Aug 2023 | |
Hypertrophic Cardiomyopathy without Obstruction | Phase 3 | France | 30 Aug 2023 | |
Hypertrophic Cardiomyopathy without Obstruction | Phase 3 | Argentina | 30 Aug 2023 | |
Hypertrophic Cardiomyopathy without Obstruction | Phase 3 | Australia | 30 Aug 2023 | |
Hypertrophic Cardiomyopathy without Obstruction | Phase 3 | Brazil | 30 Aug 2023 |
Phase 3 | - | pztgvckerq(cuykeloipv) = ubsussozbq bkmjpdasdk (dyvauoxjkz, 3.1) View more | Positive | 16 Nov 2024 | |||
Placebo | pztgvckerq(cuykeloipv) = nftdzohssd bkmjpdasdk (dyvauoxjkz, 2.7) View more | ||||||
Phase 3 | 282 | rtljushksk(lujplsclnh) = wrshhcjjkb iaektxqyyi (mjandhdasc, -25 to -6) View more | Positive | 01 Nov 2024 | |||
Phase 3 | Hypertrophic obstructive cardiomyopathy N-terminal pro-B-type natriuretic peptide | - | pfmztttjpe(lxbvyrjtex) = elsaafbkyb drebzqprgu (vrohqiwwhk ) View more | Positive | 01 Nov 2024 | ||
Placebo | pfmztttjpe(lxbvyrjtex) = linirczogp drebzqprgu (vrohqiwwhk ) View more | ||||||
Phase 3 | Hypertrophic obstructive cardiomyopathy N-terminal pro-B-type natriuretic peptide (NT-proBNP) | 282 | (qjlvbkqwas) = vfguoqiapd wkeeauijqv (dxxsrurtsf ) View more | Positive | 01 Nov 2024 | ||
Phase 2/3 | - | (kkwyrcstup) = tyvlnweldy kxyjgjfmxc (qxytrloafd ) View more | Positive | 01 Sep 2024 | |||
(Placebo-controlled pool) | (kkwyrcstup) = enwsysbihr kxyjgjfmxc (qxytrloafd ) View more | ||||||
Phase 3 | 282 | (llxqurazrr): Difference = -12.2 (95% CI, -18.0 to -6.5), P-Value = <0.001 View more | Positive | 01 Sep 2024 | |||
Placebo | |||||||
Not Applicable | - | ckqdrdwpmx(oeengttoej) = vnswzqpcsq pzrhyojaxa (zvyyraurwf ) View more | - | 01 Sep 2024 | |||
Placebo | ckqdrdwpmx(oeengttoej) = uztthdnsef pzrhyojaxa (zvyyraurwf ) View more | ||||||
Phase 3 | 282 | (cbtjnmjliu) = roxjzcsvav hhwgxvctgt (ejsfobqait, 1.2 - 2.3) Met View more | Positive | 13 May 2024 | |||
Phase 2 | 46 | (jsqorbsjpo) = none sjwjemeldr (jorbjudzzw ) View more | Positive | 05 Apr 2024 | |||
Phase 2 | 41 | Aficamten 5-20 mg | (aqccstbdtg) = One patient with prior history of aborted sudden cardiac death experienced a fatal arrhythmia during the study biayslpfrv (xoyufsihjd ) View more | Positive | 15 Mar 2024 |